Clinical Analysis of Octreotide in Varix Bleeding.
- Author:
Woon Yong KWON
1
;
Joong Sik JUNG
;
Kyu Seok KIM
;
Sung Hye KIM
;
Sang Do SIN
;
Joong Eui RHEE
;
Gil Joon SUH
;
Yeo Kyu YOUN
Author Information
1. Department of Emergency Medicine, Seoul National University Hospital, Korea. kwy711@hanmail.net
- Publication Type:Original Article
- Keywords:
Varix bleeding;
Octreotide;
Early bleeding control
- MeSH:
Balloon Occlusion;
Blood Pressure;
Classification;
Emergencies;
Esophageal and Gastric Varices;
Hemorrhage*;
Humans;
Liver Cirrhosis;
Mortality;
Octreotide*;
Prospective Studies;
Retrospective Studies;
Seoul;
Varicose Veins*;
Vital Signs
- From:Journal of the Korean Society of Emergency Medicine
2001;12(1):21-26
- CountryRepublic of Korea
- Language:Korean
-
Abstract:
PURPOSE: This study was conducted to confirm the effects of octreotide in patients with variceal bleeding. METHODS: We performed a retrospective analysis of 26 patients with variceal bleeding, who visited the Emergency Center of Seoul National University Hospital from January 1st to June 31st, 1996, the control group, and a prospective analysis of 28 patients with variceal bleeding, who visited the Emergency Center of Seoul National University Hospital from March 1st to August 31st, 1999, for the octreotideinfused group. The octreotide-infused group recieved a continuous infusion of octreotide, 25 microgram/hr, for 5 days after an initial bolus of 50 microgram. When active bleeding continued over 1 hour, over 5 pints of packed-RBC were needed for transfusion within 24 hours, or when the systolic blood pressure was under 90 mmHg, a ballon tamponade with Sengstaken-Blackemore tube was used. T-test and X2 test were used for statistical analysis(p<0.05). RESULTS: Forty-one patients were male(octreotide-infused group 22, control group 19) and 13 were female(octreotide-infused group 6, control group 7). The mean age was 55 years(octreotide-infused group 56 years, control group 52 years). There were no significant differences in vital signs, hemoglobin/hematocrit levels, and Child-Pugh's classifications between the octreotide-infused group and the control group initially. There was a significant difference in the rates of early bleeding control within 24 hours(p<0.05), but there were no significant differences in the rates of rebleeding, mortality within 1 week, and use of a balloon tamponade. CONCLUSION: Variceal bleeding is a serious complication of liver cirrhosis and has a high mortality rate. Octreotide is an effective vasoactive agent for control of early bleeding. Thus, octreotide should be used first before endoscopic definitive therapies, to stabilize the vital signs of patients and to secure a field for endoscopic procedures.
